Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...

I am interested in knowing how long it might take for someone who discontinued all medications that have been taken for years to have serious or dire ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Dear F.W.: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope ...

Subsequent annual testing has shown little to no progression. I take levothyroxine, Eliquis, verapamil and pravastatin. I’ve ...

Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...